Conclusions: 12-month hospital costs for TAVI and SAVR are similar. TAVI costs are largely driven by cost of the prosthesis; SAVR costs are driven by hospital length of stay and ICU hours. A comparative analysis of outcomes for TAVI and SAVR is required to further inform health policy decisionmaking.
Background: The recent PARTNER S3i trial compared transcatheter aortic valve implantation (TAVI) using the third-generation SAPIEN 3 device to surgical aortic valve replacement (SAVR) in intermediate-risk patients with severe symptomatic aortic stenosis. Using data from PARTNER S3i, we performed a contemporary cost-effectiveness analysis of current-generation TAVI versus SAVR from the Australian healthcare system perspective.
Methods: A Markov model with monthly cycles and a ten-year horizon was constructed to estimate costs, life-years and quality adjusted life-years (QALYs) associated with TAVI and SAVR. Efficacy inputs were derived from the PART-NER S3i study. Costs were estimated from published sources. Deterministic and probabilistic sensitivity analyses were performed to assess model uncertainty.
Results: TAVI was found to have higher immediate procedural costs than SAVR, driven primarily by the cost of the transcatheter valve. This was offset by a shorter length of hospitalisation following TAVI, such that the combined cost of initial procedure and hospitalisation was lower in TAVI compared to SAVR. With 5% annual discounting, total costs over a ten-year horizon were $50,144 in TAVI and $60,085 in SAVR, and TAVI was found to produce 0.33 more life years and 0.31 more QALYs than SAVR. Thus, from a health economic perspective, TAVI was dominant compared to SAVR. Results were robust to sensitivity analyses, with TAVI being dominant in 70% of 10,000 Monte Carlo iterations and costeffective in 92% of iterations at a willingness-to-pay threshold of $50,000/QALY gained.
Conclusions: TAVI is likely to be highly cost-effective compared to SAVR in management of severe symptomatic aortic stenosis. 
